Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.43

0.0%

Dec 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: inpursuit who wrote (769)	10/1/2000 10:55:25 AM
From: scaram(o)uche	Read Replies (2) of 1475

It's designed to bring the efforts of Imutran, BTRN and Novartis together in an entrepreneurial company. BTRN gets 1/3 of anything new that comes out of the company for non-xeno applications. Otherwise, it's royalty city. There were actually some parts of xeno research at BTRN that Novartis didn't have rights to. Now they do. Note the now even stronger presence in stem cells, moving forward. BTRN instantly inherits the benefits of the Imutran collaboration with Infigen. No, I honestly believe that you want Novartis to be actively engaged in this company.... they seem to have a knack, last five years or so, for letting innovation run. HQ in the BTRN facility until they find independent space. I've heard one report that it will be business as usual with Sachs, Sykes, et al. at MGH, but need to verify. That's a big part of the story, for me, and I'd be a happy camper.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next